Affordable Access

Publisher Website

Labetalol infusion for refractory hypertension causing severe hypotension and bradycardia: an issue of patient safety.

Authors
  • 1
Type
Published Article
Journal
Patient Safety in Surgery
1754-9493
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Volume
2
Pages
13–13
Identifiers
DOI: 10.1186/1754-9493-2-13
PMID: 18505576
Source
Medline

Abstract

Incremental doses of intravenous labetalol are safe and effective and, at times, such therapy may need to be augmented by a continuous infusion of labetalol to control severe hypertension. Continuous infusions of labetalol may exceed the recommended maximum daily dose of 300 mg on occasion. We report a case in which hypertension occurring after an abdominal aortic aneurysm repair, initially responsive to intermittent intravenous beta-blockade, became resistant to this therapy leading to the choice of an intravenous labetalol infusion as the therapeutic option. The labetalol infusion resulted in a profound cardiovascular compromise in this postoperative critically ill patient. While infusions of labetalol have successfully been used, prolonged administration in the intensive care unit requires vigilance and the establishment of a therapeutic rationale/policy for interventions, such as the ready availability of glucagon, beta-agonists, phosphodiesterase inhibitors, insulin, and vasopressin when severe cardiovascular depression occurs.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F